MexACLF is the second clinical trial sponsored by MexBrain and taking place in Lyon, at Hôpital Croix Rousse. It aims to include patients with Acute on Chronic Liver Failure (ACLF) to evaluate safety and free metal extraction capabilities of the Mexbrain’s treatment. 

ACLF is a syndrome of abrupt decompensation of cirrhosis, usually of unknown cause, which may be due to infection or active alcoholism, but in 40-50% of cases the etiology remains unexplained. This particular form of decompensation is associated with a high mortality rate, up to 80% at advanced stages with multi-organ failures. No effective treatment exists to date. 

An excessive inflammatory response, associated with a high level of “bad free iron” in the blood, seems to play an important role in the development of ACLF. MexBrain’s treatment combines chelating biopolymers and hemodialysis to achieve greater extraction speed, greater specificity and above all greater safety compared with solutions currently on the market. MexBrain’s treatment uses a very low volume of dialysis fluid, enabling efficient and specific extraction of free metals present in the blood in a short time, while limiting side effects.